Amber, PA, United States of America

Henryk Mach

USPTO Granted Patents = 4 


Average Co-Inventor Count = 19.0

ph-index = 3

Forward Citations = 183(Granted Patents)


Location History:

  • Ambler, PA (US) (2012)
  • Amber, PA (US) (2014 - 2015)

Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Henryk Mach

Introduction

Henryk Mach is a notable inventor based in Amber, Pennsylvania, with a focus on developing innovative solutions in the field of biochemistry. He holds a total of four patents, showcasing his contributions to medical science, particularly in the treatment of conditions associated with PCSK9 activity.

Latest Patents

Among his latest patents are two significant inventions related to PCSK9 antagonists. The first patent, 1B20 PCSK9 antagonists, discloses antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9). These antagonists are effective in inhibiting PCSK9 function, making them desirable for treating conditions linked to PCSK9 activity. This patent also includes nucleic acid encoding for the antagonists, vectors, host cells, and compositions that comprise these antagonists. Additionally, methods for creating PCSK9-specific antagonists and their applications for inhibiting or antagonizing PCSK9 function are detailed in this patent. The second patent, 1D05 PCSK9 antagonists, shares similar innovations, further emphasizing the importance of these antagonists in medical treatments.

Career Highlights

Henryk Mach has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp., where he has contributed to significant advancements in drug development and biochemistry.

Collaborations

Throughout his career, Henryk has collaborated with notable professionals in his field, including Jon H. Condra and Rose M. Cubbon. These collaborations have likely enriched his research and development efforts, leading to impactful innovations.

Conclusion

Henryk Mach's work in developing PCSK9 antagonists represents a significant advancement in the treatment of related medical conditions. His contributions to the field of biochemistry and his collaborations with esteemed colleagues highlight his commitment to innovation and improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…